Athira Pharma To Focus On Advancement Of ATH-1105 For The Treatment Of Neurodegenerative Diseases, Includes A Reduction In Workforce Of ~70%. Athira Expects One-Time Costs Of ~$2.8M And Cost Savings Of ~$13.4M On An Annualized Basis
Athira Pharma To Focus On Advancement Of ATH-1105 For The Treatment Of Neurodegenerative Diseases, Includes A Reduction In Workforce Of ~70%. Athira Expects One-Time Costs Of ~$2.8M And Cost Savings Of ~$13.4M On An Annualized Basis
In alignment with Athira's focus on continued development of ATH-1105, the Company is implementing cost containment measures including a reduction in workforce of approximately 70%. Athira expects one-time costs of approximately $2.8 million and cost savings of approximately $13.4 million on an annualized basis related to the reduction in the workforce. As a result of these cost containment measures and based on its current operating plan, Athira now expects to extend its cash runway into the first quarter of 2026. Moving forward, the Company will review and consider various options including partnering and financing with the intent of extending its cash runway to achieve initial proof-of-concept and enable further development for ATH-1105 in neurodegenerative diseases.ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
ATH-1105是一种口服给药的神经营养因子HGF系统的正调节剂，目前正在进行第一阶段的临床试验，预计将于2024年底完成，并预计于2025年开始给予ALS患者剂量。
Company announces cost containment measures in alignment with focus on advancing ATH-1105
公司宣布采取成本控制措施，以推进ATH-1105的发展。
BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following the topline data readout from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease (AD) the Company plans to focus on advancing the clinical development program for ATH-1105 as a potential treatment for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and AD. ATH-1105 is the Company's oral, next-generation small molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system currently in development for the treatment of ALS.
华盛顿州Bothell，2024年9月17日（环球新闻社） - Athira Pharma, Inc.（纳斯达克：ATHA）是一家临床阶段生物制药公司，专注于开发小分子化合物来恢复神经细胞健康和减缓神经退行性疾病。今天宣布，在Phase 2/3 LIFt-AD临床试验中，使用fosgonimeton治疗阿尔茨海默病（AD）的头榜数据公布后，公司计划专注于推进ATH-1105的临床开发计划，作为治疗神经退行性疾病（包括肌萎缩性脊髓侧索硬化症（ALS）和AD）的潜在治疗方法。ATH-1105是公司的口服、下一代小分子化合物神经营养因子肝细胞生长因子（HGF）系统的正调节剂，目前正在ALS的治疗领域开发中。
In alignment with Athira's focus on continued development of ATH-1105, the Company is implementing cost containment measures including a reduction in workforce of approximately 70%. Athira expects one-time costs of approximately $2.8 million and cost savings of approximately $13.4 million on an annualized basis related to the reduction in the workforce. As a result of these cost containment measures and based on its current operating plan, Athira now expects to extend its cash runway into the first quarter of 2026. Moving forward, the Company will review and consider various options including partnering and financing with the intent of extending its cash runway to achieve initial proof-of-concept and enable further development for ATH-1105 in neurodegenerative diseases.
为了配合Athira继续开发ATH-1105的重点，该公司正在实施成本控制措施，包括裁员约70%。Athira预计裁员将产生约280万美元的一次性费用，并在年度基础上节约约1340万美元。基于目前的运营计划，Athira预计现金储备将延长至2026年第一季度。未来，该公司将审查和考虑各种选择，包括合作伙伴和融资，以延长现金储备，实现初步概念验证并推动ATH-1105在神经退行性疾病领域的进一步发展。